1 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05111
D05111
|
Nalmefene
| [1] 6 6 |
2 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05113
D05113
|
Naltrexone
| [13] 6 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 |
3 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D05312
D05312
|
Oxycodone
| [5] 6 6, 13, 70, 226, 298 |
4 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08144
D08144
|
Loperamide
| [2] 13 13, 97 |
5 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08246
D08246
|
Nalbuphine
| [1] 85 85 |
6 |
OPRD1
| [3] cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction | D08249
D08249
|
Naloxone
| [2] 6 6, 226 |